Home Cart Sign in  
Chemical Structure| 869113-09-7 Chemical Structure| 869113-09-7

Structure of Umeclidinium bromide
CAS No.: 869113-09-7

Chemical Structure| 869113-09-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Umeclidinium bromide is a long-acting mAchR antagonist with Ki values ranging in 0.05 to 0.16 nM for the cloned human M1-M5 mAChRs.

Synonyms: GSK573719A; Umeclidinium (bromide); GSK-573719, GSK573719, GSK 573719, GSK-573719A, GSK573719A, GSK 573719A, Incruse Ellipta, Umeclidinium bromide

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Umeclidinium bromide

CAS No. :869113-09-7
Formula : C29H34BrNO2
M.W : 508.49
SMILES Code : OC(C1(CC2)CC[N+]2(CCOCC3=CC=CC=C3)CC1)(C4=CC=CC=C4)C5=CC=CC=C5.[Br-]
Synonyms :
GSK573719A; Umeclidinium (bromide); GSK-573719, GSK573719, GSK 573719, GSK-573719A, GSK573719A, GSK 573719A, Incruse Ellipta, Umeclidinium bromide
MDL No. :MFCD27976798
InChI Key :PEJHHXHHNGORMP-UHFFFAOYSA-M
Pubchem ID :11519069

Safety of Umeclidinium bromide

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • mAChR

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00976144 Pulmonary Disease, Chronic Obs... More >>tructive Less << PHASE1 COMPLETED 2009-09-22 GSK Investigational Site, Rand... More >>wick, New South Wales, 2031, Australia Less <<
NCT01702363 Pulmonary Disease, Chronic Obs... More >>tructive Less << PHASE3 COMPLETED 2025-12-13 GSK Investigational Site, Fuku... More >>oka, 811-1347, Japan|GSK Investigational Site, Gunma, 371-0048, Japan|GSK Investigational Site, Hokkaido, 080-0805, Japan|GSK Investigational Site, Hyogo, 670-0849, Japan|GSK Investigational Site, Ibaraki, 300-0053, Japan|GSK Investigational Site, Ibaraki, 302-0022, Japan|GSK Investigational Site, Ishikawa, 920-8610, Japan|GSK Investigational Site, Kanagawa, 239-0821, Japan|GSK Investigational Site, Kyoto, 601-1495, Japan|GSK Investigational Site, Miyagi, 983-0824, Japan|GSK Investigational Site, Nagano, 391-0011, Japan|GSK Investigational Site, Oita, 870-0921, Japan|GSK Investigational Site, Oita, 876-0047, Japan|GSK Investigational Site, Osaka, 530-0001, Japan|GSK Investigational Site, Osaka, 589-0022, Japan|GSK Investigational Site, Shizuoka, 436-0022, Japan|GSK Investigational Site, Tokyo, 103-0027, Japan|GSK Investigational Site, Tokyo, 153-8934, Japan|GSK Investigational Site, Tokyo, 192-0903, Japan|GSK Investigational Site, Yamanashi, 400-0031, Japan Less <<
NCT00475436 Pulmonary Disease, Chronic Obs... More >>tructive Less << PHASE1 COMPLETED 2007-09-18 GSK Investigational Site, Berl... More >>in, 14050, Germany Less <<
NCT00732472 Pulmonary Disease, Chronic Obs... More >>tructive Less << PHASE2 COMPLETED 2025-08-09 GSK Investigational Site, Read... More >>ing, Berkshire, RG2 0TG, United Kingdom|GSK Investigational Site, Buckshaw Village, Chorley, Lancashire, PR7 7NA, United Kingdom|GSK Investigational Site, Waterloo, Liverpool, Merseyside, L22 0LG, United Kingdom|GSK Investigational Site, Clydebank, Glasgow, G81 2DR, United Kingdom|GSK Investigational Site, Edgbaston, Birmingham, B15 2SQ, United Kingdom|GSK Investigational Site, Llanishen, CF14 5GJ, United Kingdom|GSK Investigational Site, Manchester, M15 6SX, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.97mL

0.39mL

0.20mL

9.83mL

1.97mL

0.98mL

19.67mL

3.93mL

1.97mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories